Author's response to reviews Title: Customized chemotherapy based on epidermal growth factor receptor mutation status for elderly patients with advanced non-small-cell lung cancer: a phase II trial Authors:
نویسندگان
چکیده
Shiro Fujita ([email protected]) Nobuyuki Katakami ([email protected]) Katsuhiro Masago ([email protected]) Hiroshige Yoshioka ([email protected]) Keisuke Tomii ([email protected]) Toshihiko Kaneda ([email protected]) Masataka Hirabayashi ([email protected]) Kei Kunimasa ([email protected]) Toshio Morizane ([email protected]) Tadashi Mio ([email protected])
منابع مشابه
A phase II study of pemetrexed in chemotherapy-naive elderly patients aged ≥ 75 years with advanced non-squamous non-small-cell lung cancer (HANSHIN Oncology Group 003).
OBJECTIVE Pemetrexed has relatively mild toxicity and possibly can be administered long term to patients with non-small-cell lung cancer. We conducted a Phase II trial to evaluate the efficacy and safety of pemetrexed in chemotherapy-naïve elderly patients with advanced non-squamous non-small-cell lung cancer. METHODS In this multicenter Phase II trial, we recruited elderly patients with non-...
متن کاملMulticentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the west Japan thoracic oncology group trial
with clinical response to gefitinib therapy. Science 2004; 304: 1497–1500. 3. Inoue A, Suzuki T, Fukuhara T et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006; 24: 3340–3346. 4. Asahina H, Yamazaki K, Kinoshita I et al. A phase II trial of gefitinib as fir...
متن کاملExpression of Epidermal Growth Factor Receptor and the association with Demographic and Prognostic Factors in Patients with Non-small Cell Lung Cancer
Introduction: Growth, proliferation, survival, and differentiation are the prominent characteristics of cells, which are affected by cancer. Epidermal growth factor receptor (EGFR) plays a pivotal role in the effective control of these features. Given the significance of EGFR signaling pathway in non-small cell lung cancer (NSCLC), EGFR expression is influential on these cell characteristics. I...
متن کاملمقایسه تأثیر شیمیدرمانی استاندارد و اثر ترکیبی آن با Cetuximab بر میزان بقاء در مبتلایان به سرطان پیشرفته کولون
Background and Aim: Recent advances in molecular and cellular biology and the importance of Epidermal growth factor receptor(EGFR) in the development and progression of many solid malignancies such as Colorectal Cancer (CRC) and non- small cell lung cancer have allowed rapid advances in rational drug design and targeted therapies for malignancies.Cetuximab or Erbitux, an IgG1 monoclonal antib...
متن کاملAntibodies to the epidermal growth factor receptor in non small cell lung cancer: current status of matuzumab and panitumumab.
Matuzumab and panitumumab are antibodies against the epidermal growth factor receptor (EGFR) that are being evaluated in several malignancies including non-small cell lung cancer (NSCLC). In phase I trials of single-agent matuzumab in patients with EGFR-positive cancer, three tumor responses were documented in esophageal squamous cell carcinoma as well as colorectal carcinoma. A phase I trial o...
متن کامل